Literature DB >> 24369807

Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease.

Katharine M Woessner1, Andrew A White2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24369807     DOI： 10.1016/j.jaci.2013.11.016

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

Review 1.  Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).

Authors:  Ronald A Simon; Kristen M Dazy; Jeremy D Waldram
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

2.  Aspirin allergy labeling after desensitization: education, communication, and patient safety.

Authors:  Jyotsna Mullur; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-22

Review 3.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 4.  Aspirin-exacerbated respiratory disease and current treatment modalities.

Authors:  Emine Güven Sakalar; Nuray Bayar Muluk; Murat Kar; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-18       Impact factor: 2.503

Review 5.  Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Lucyna Mastalerz; Katarzyna E Tyrak
Journal:  Clin Transl Allergy       Date:  2021-08-13       Impact factor: 5.871

6.  PGD2 deficiency exacerbates food antigen-induced mast cell hyperplasia.

Authors:  Tatsuro Nakamura; Shingo Maeda; Kazuhide Horiguchi; Toko Maehara; Kosuke Aritake; Byung-Il Choi; Yoichiro Iwakura; Yoshihiro Urade; Takahisa Murata
Journal:  Nat Commun       Date:  2015-07-10       Impact factor: 14.919

7.  Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.

Authors:  Sharan J Shah; Waleed M Abuzeid; Anusha Ponduri; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; David Rosenstreich; Denisa Ferastraoaru; Elina Jerschow
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-30       Impact factor: 3.858

8.  Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results.

Authors:  Saltuk Buğra Kaya; Mehmet Erdem Çakmak; Ebru Damadoğlu; Gül Karakaya; Ali Fuat Kalyoncu
Journal:  Turk Thorac J       Date:  2021-09

Review 9.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.